Saturday, Sep 23, 2023

How Exscientia Reduces Drug Discovery Time With Gen AI

Company Addresses Speed, Cost, Efficacy and Safety Issues With Application of Gen AI
U.K.-based Exscientia, a leading drug discovery firm, has successfully advanced six molecules created with the help of generative AI into Phase 1 clinical trials. CEO and founder Andrew Hopkins envisions a future where AI plays a vital role in the design of all new therapies.